These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 23807172

  • 1. Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
    Wan J, Liu T, Mei L, Li J, Gong K, Yu C, Li W.
    Br J Cancer; 2013 Jul 23; 109(2):342-50. PubMed ID: 23807172
    [Abstract] [Full Text] [Related]

  • 2. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
    Li J, Chen Y, Wan J, Liu X, Yu C, Li W.
    Br J Pharmacol; 2014 Jul 23; 171(13):3182-95. PubMed ID: 24571452
    [Abstract] [Full Text] [Related]

  • 3. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M, Fei Z, Zhang G.
    Biomed Pharmacother; 2018 Jan 23; 97():1282-1288. PubMed ID: 29156516
    [Abstract] [Full Text] [Related]

  • 4. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 23; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
    Tan W, Zhu S, Cao J, Zhang L, Li W, Liu K, Zhong J, Shang C, Chen Y.
    Oncol Res; 2017 Nov 02; 25(9):1543-1553. PubMed ID: 28276313
    [Abstract] [Full Text] [Related]

  • 6. Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma.
    Liu C, Gong K, Mao X, Li W.
    Int J Cancer; 2011 Sep 15; 129(6):1519-31. PubMed ID: 21128229
    [Abstract] [Full Text] [Related]

  • 7. Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21.
    Mei L, Chen Y, Wang Z, Wang J, Wan J, Yu C, Liu X, Li W.
    Br J Pharmacol; 2015 May 15; 172(9):2232-45. PubMed ID: 25521075
    [Abstract] [Full Text] [Related]

  • 8. Autophagy-related gene 7 (ATG7) and reactive oxygen species/extracellular signal-regulated kinase regulate tetrandrine-induced autophagy in human hepatocellular carcinoma.
    Gong K, Chen C, Zhan Y, Chen Y, Huang Z, Li W.
    J Biol Chem; 2012 Oct 12; 287(42):35576-35588. PubMed ID: 22927446
    [Abstract] [Full Text] [Related]

  • 9. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T.
    J Hematol Oncol; 2016 Mar 08; 9():20. PubMed ID: 26957312
    [Abstract] [Full Text] [Related]

  • 10. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ.
    Oncotarget; 2016 Jun 14; 7(24):36767-36782. PubMed ID: 27167344
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
    Alsaied OA, Sangwan V, Banerjee S, Krosch TC, Chugh R, Saluja A, Vickers SM, Jensen EH.
    Surgery; 2014 Aug 14; 156(2):270-9. PubMed ID: 24953273
    [Abstract] [Full Text] [Related]

  • 12. Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells.
    Lange M, Abhari BA, Hinrichs TM, Fulda S, Liese J.
    Biochem Pharmacol; 2016 Oct 15; 118():9-17. PubMed ID: 27544320
    [Abstract] [Full Text] [Related]

  • 13. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
    Ou DL, Lee BS, Chang YC, Lin LI, Liou JY, Hsu C, Cheng AL.
    PLoS One; 2013 Oct 15; 8(6):e66589. PubMed ID: 23818948
    [Abstract] [Full Text] [Related]

  • 14. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z, Wu J, Wu J, Luo D, Jiang C, Ding Y.
    J Exp Clin Cancer Res; 2016 Sep 30; 35(1):159. PubMed ID: 27716356
    [Abstract] [Full Text] [Related]

  • 15. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF.
    Cancer Lett; 2016 Feb 28; 371(2):205-13. PubMed ID: 26679051
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Br J Pharmacol; 2013 Feb 28; 168(3):658-72. PubMed ID: 22978563
    [Abstract] [Full Text] [Related]

  • 17. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo.
    Tsai JJ, Hsu FT, Pan PJ, Chen CW, Kuo YC.
    Anticancer Res; 2018 Apr 28; 38(4):2119-2125. PubMed ID: 29599330
    [Abstract] [Full Text] [Related]

  • 18. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B, Zhang X, Sun B, Cao L, Zhao L, Li J, Ge N, Chen L, Qian H, Yin Z.
    Tumour Biol; 2016 Jun 28; 37(6):8047-55. PubMed ID: 26711788
    [Abstract] [Full Text] [Related]

  • 19. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H, Zhang C, Chi H, Meng Z.
    Int J Oncol; 2018 Jun 28; 52(6):2051-2060. PubMed ID: 29620259
    [Abstract] [Full Text] [Related]

  • 20. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S, Sun X.
    Cancer Lett; 2014 Dec 01; 355(1):96-105. PubMed ID: 25218350
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.